SCHEMBL16377909

SCHEMBL16377909

COc1nccc(NC(=O)C(C)(C)C)c1C=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.39
LMNA P02545 2/20 0.38
TOP2A P11388 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
ALOX12 P18054 1/20 0.37
CETP P11597 1/20 0.37
POLB P06746 1/20 0.36
PDK1 Q15118 1/20 0.35
PDK2 Q15119 1/20 0.35
PDK3 Q15120 1/20 0.35
PDK4 Q16654 1/20 0.35
MAPT P10636 3/20 0.35
ALDH1A1 P00352 2/20 0.35
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
TSHR P16473 1/20 0.34
F2 P00734 1/20 0.34
HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30937539 0.84 ATR (0.47) KDM4ERAB9A
SCHEMBL16856823 0.82 LMNA (0.44) KDM4ELMNATOP2AL3MBTL1CETP
SCHEMBL7125030 0.81 L3MBTL1 (0.41) KDM4ELMNATOP2AL3MBTL1CETP
SCHEMBL29956074 0.78 KDM4E (0.39) KDM4ELMNATOP2AL3MBTL1ALOX12
SCHEMBL16857151 0.78 TOP2A (0.38) KDM4ELMNATOP2AL3MBTL1CETP
SCHEMBL16857291 0.78 TOP2A (0.38) KDM4ELMNATOP2AL3MBTL1CETP
SCHEMBL29958183 0.78 L3MBTL1 (0.38) KDM4ELMNATOP2AL3MBTL1ALOX12
SCHEMBL16856956 0.77 TOP2A (0.38) KDM4ELMNATOP2AL3MBTL1CETP
SCHEMBL8495853 0.77 CETP (0.47) KDM4ELMNAALOX12CETPPOLB
SCHEMBL16857100 0.76 TMIGD3 (0.39) KDM4ELMNATOP2AL3MBTL1CETP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3567040-B1 METHOD FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE SYNTHESIS OF [1,2,4]-TRIAZOLO[4,3-A]PYRIDINES AMGEN INC (US) 2020-09-09 EP disclosed
EP-3567040-A1 METHOD FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE SYNTHESIS OF [1,2,4]-TRIAZOLO[4,3-A]PYRIDINES Amgen, Inc (US) 2019-11-13 EP disclosed
EP-3013825-B1 METHOD FOR THE PREPARATION OF (1,2,4)-TRIAZOLO(4,3-A)PYRIDINES AMGEN INC (US) 2019-08-07 EP disclosed
US-9643984-B2 Method for the preparation of [1,2,4]-triazolo[4,3-a]pyridines AMGEN INC. (US) 2017-05-09 US disclosed
US-9643984-B2 Method for the preparation of [1,2,4]-triazolo[4,3-a]pyridines AMGEN INC. (US) 2017-05-09 US disclosed
US-20160347769-A1 METHOD FOR THE PREPARATION OF [1,2,4]-TRIAZOLO[4,3-A]PYRIDINES AMGEN INC. 2016-12-01 US disclosed
US-20160347769-A1 METHOD FOR THE PREPARATION OF [1,2,4]-TRIAZOLO[4,3-A]PYRIDINES AMGEN INC. 2016-12-01 US disclosed
WO-2014210042-A2 METHOD FOR THE PREPARATION OF (1,2,4)-TRIAZOLO(4,3-A)PYRIDINES AMGEN INC. (US) 2014-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160347769-A1 METHOD FOR THE PREPARATION OF [1,2,4]-TRIAZOLO[4,3-A]PYRIDINES H1-4, H1-5, H1-3 KDM4E 452/4885LMNA 462/4885TOP2A 169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.